Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Fellow Novavax Stockholders: As a long-term strategic investor, we have been engaging with the board of directors of Novavax (the "Board") for over a year in an attempt to unlock value on behalf of all of its shareholders, so it is heartening that our campaign has begun to deliver positive results. We long advocated for Novavax to explore potential strategic partnership opportunities and believe that the Company's recent announcement ...

The biotech still hasn't lost momentum. Vaccine maker Novavax (NVAX -9.65%) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might sink soon -- Novavax reported positive developments in its latest quarterly update that doubled its share price in just one day. The biotech has come a long way since its not-so-successful attempt at dominating the coronavirus vaccine market. But do more recent developments make Novavax's stock a bu ...

In return, Novavax will get an influx of cash. Sanofi will pay $500 million upfront, and Novavax could get another $700 million depending on development and regulatory milestones. Novavax coulf also receive up to $200 million, plus royalties, "for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M adjuvant technology." The cash gives Novavax a lot more stability. It has previously raised a "going concern risk" about its business, which means there are doub ...

In fact, consistently beating the S&P 500 — in good times and bad — has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, has outperformed the S&P 500 each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less o ...

The first point to note is that Riot ended Q1 2024 with a cash buffer (including Bitcoin (BTC-USD) holdings) of $1.3 billion. Further, with a zero-debt balance sheet, the company has high financial flexibility to pursue aggressive growth. It's also worth noting that the company has set an ambitious target of increasing hash rate capacity from 12.4 EH/s in Q1 2024 to 31.5 EH/s by the end of the year. If Bitcoin remains in an uptrend, this expansion will translate into stellar revenue and EBITDA growth. The m ...

Novavax entered the coronavirus vaccine market late, missing out on the biggest revenue opportunity. This disappointed investors, and the stock plummeted more than 90% from its high. But recent news -- a big partnership with pharmaceutical giant Sanofi -- and Novavax's progress with newer vaccine candidates signal brighter days may be ahead. Could Novavax carve out share in the vaccine market and potentially become the next Moderna? Let's find out. Novavax's $1.2 billion deal Last week, Novavax announced a ...

The S&P 500 is on the longest streak since February, partly buoyed by stocks with analyst upgrades. The Dow Jones Industrial Average is also increasing amid mixed economic signals, as consumer sentiment dropped to a six-month low due to heightened short-term inflation expectations. With the potential risk of 'stagflation' on the horizon, the markets may have to adjust to this possibility. Treasury 10-year yields again increased, and traders have fully anticipated a rate cut by November, with a second move l ...

A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy. A big name in COVID-19 care Much of Novavax's name recognition comes from the thick of the COVID-19 pandemic, as the company developed one of only four vaccines for the disease that got emergency use authorization from the U.S. Food and Drug Administration. That's a tough act to follow, and Novavax hasn't yet proven it can build out a long-term, sustainable business. So, like Smith, I can envision more downside ...

Novavax shares have soared and plummeted in recent years. The company also announced positive clinical-trial data for its combined flu/coronavirus vaccine candidate and aims to launch a phase 3 trial in the second half of this year. Finally, Novavax holds a key asset, one that could brighten the earnings picture. I'm talking about the company's Matrix-M adjuvant technology -- an ingredient that boosts the immune system's response to a particular vaccine. Novavax uses Matrix-M in its vaccine and candidates, ...

Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer. Shares of the struggling vaccine developer Novavax (NVAX 47.63%) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global pharmaceutical giant that wants to market Novavax's COVID-19 and influenza vaccines. The recent Novavax stock rally continued after the weekend and investors are right to wonder if it has more fuel to climb higher ...